297 related articles for article (PubMed ID: 32402285)
1. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer.
Brunton H; Caligiuri G; Cunningham R; Upstill-Goddard R; Bailey UM; Garner IM; Nourse C; Dreyer S; Jones M; Moran-Jones K; Wright DW; Paulus-Hock V; Nixon C; Thomson G; Jamieson NB; McGregor GA; Evers L; McKay CJ; Gulati A; Brough R; Bajrami I; Pettitt SJ; Dziubinski ML; Barry ST; Grützmann R; Brown R; Curry E; ; ; Pajic M; Musgrove EA; Petersen GM; Shanks E; Ashworth A; Crawford HC; Simeone DM; Froeling FEM; Lord CJ; Mukhopadhyay D; Pilarsky C; Grimmond SE; Morton JP; Sansom OJ; Chang DK; Bailey PJ; Biankin AV
Cell Rep; 2020 May; 31(6):107625. PubMed ID: 32402285
[TBL] [Abstract][Full Text] [Related]
2. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
Eyres M; Lanfredini S; Xu H; Burns A; Blake A; Willenbrock F; Goldin R; Hughes D; Hughes S; Thapa A; Vavoulis D; Hubert A; D'Costa Z; Sabbagh A; Abraham AG; Blancher C; Jones S; Verrill C; Silva M; Soonawalla Z; Maughan T; Schuh A; Mukherjee S; O'Neill E
Gastroenterology; 2021 Aug; 161(2):653-668.e16. PubMed ID: 33915173
[TBL] [Abstract][Full Text] [Related]
3. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
[TBL] [Abstract][Full Text] [Related]
4. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.
Martinelli P; Madriles F; Cañamero M; Pau EC; Pozo ND; Guerra C; Real FX
Gut; 2016 Mar; 65(3):476-86. PubMed ID: 25596178
[TBL] [Abstract][Full Text] [Related]
5. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer.
Duan K; Jang GH; Grant RC; Wilson JM; Notta F; O'Kane GM; Knox JJ; Gallinger S; Fischer S
Sci Rep; 2021 Jul; 11(1):14951. PubMed ID: 34294813
[TBL] [Abstract][Full Text] [Related]
6. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
Noll EM; Eisen C; Stenzinger A; Espinet E; Muckenhuber A; Klein C; Vogel V; Klaus B; Nadler W; Rösli C; Lutz C; Kulke M; Engelhardt J; Zickgraf FM; Espinosa O; Schlesner M; Jiang X; Kopp-Schneider A; Neuhaus P; Bahra M; Sinn BV; Eils R; Giese NA; Hackert T; Strobel O; Werner J; Büchler MW; Weichert W; Trumpp A; Sprick MR
Nat Med; 2016 Mar; 22(3):278-87. PubMed ID: 26855150
[TBL] [Abstract][Full Text] [Related]
7. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
O'Kane GM; Grünwald BT; Jang GH; Masoomian M; Picardo S; Grant RC; Denroche RE; Zhang A; Wang Y; Lam B; Krzyzanowski PM; Lungu IM; Bartlett JMS; Peralta M; Vyas F; Khokha R; Biagi J; Chadwick D; Ramotar S; Hutchinson S; Dodd A; Wilson JM; Notta F; Zogopoulos G; Gallinger S; Knox JJ; Fischer SE
Clin Cancer Res; 2020 Sep; 26(18):4901-4910. PubMed ID: 32156747
[TBL] [Abstract][Full Text] [Related]
8. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1.
Zhong Y; Wang Z; Fu B; Pan F; Yachida S; Dhara M; Albesiano E; Li L; Naito Y; Vilardell F; Cummings C; Martinelli P; Li A; Yonescu R; Ma Q; Griffin CA; Real FX; Iacobuzio-Donahue CA
PLoS One; 2011; 6(7):e22129. PubMed ID: 21811562
[TBL] [Abstract][Full Text] [Related]
9. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer.
Kloesch B; Ionasz V; Paliwal S; Hruschka N; Martinez de Villarreal J; Öllinger R; Mueller S; Dienes HP; Schindl M; Gruber ES; Stift J; Herndler-Brandstetter D; Lomberk GA; Seidler B; Saur D; Rad R; Urrutia RA; Real FX; Martinelli P
Gut; 2022 Apr; 71(4):766-777. PubMed ID: 33846140
[TBL] [Abstract][Full Text] [Related]
10. GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery.
van Eijck CWF; Real FX; Malats N; Vadgama D; van den Bosch TPP; Doukas M; van Eijck CHJ; Mustafa DAM;
Cell Rep Med; 2024 May; 5(5):101557. PubMed ID: 38733987
[TBL] [Abstract][Full Text] [Related]
11. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
12. GATA6-AS1 suppresses epithelial-mesenchymal transition of pancreatic cancer under hypoxia through regulating SNAI1 mRNA stability.
Zhou Y; Zhou X; Ben Q; Liu N; Wang J; Zhai Y; Bao Y; Zhou L
J Transl Med; 2023 Dec; 21(1):882. PubMed ID: 38057853
[TBL] [Abstract][Full Text] [Related]
13. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Daemen A; Peterson D; Sahu N; McCord R; Du X; Liu B; Kowanetz K; Hong R; Moffat J; Gao M; Boudreau A; Mroue R; Corson L; O'Brien T; Qing J; Sampath D; Merchant M; Yauch R; Manning G; Settleman J; Hatzivassiliou G; Evangelista M
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4410-7. PubMed ID: 26216984
[TBL] [Abstract][Full Text] [Related]
14. Identification of a primitive intestinal transcription factor network shared between esophageal adenocarcinoma and its precancerous precursor state.
Rogerson C; Britton E; Withey S; Hanley N; Ang YS; Sharrocks AD
Genome Res; 2019 May; 29(5):723-736. PubMed ID: 30962179
[TBL] [Abstract][Full Text] [Related]
15. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma.
de Andrés MP; Jackson RJ; Felipe I; Zagorac S; Pilarsky C; Schlitter AM; Martinez de Villareal J; Jang GH; Costello E; Gallinger S; Ghaneh P; Greenhalf W; Knösel T; Palmer DH; Ruemmele P; Weichert W; Buechler M; Hackert T; Neoptolemos JP; Notta F; Malats N; Martinelli P; Real FX
Gut; 2023 Mar; 72(3):535-548. PubMed ID: 36109153
[TBL] [Abstract][Full Text] [Related]
16. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.
Martinelli P; Carrillo-de Santa Pau E; Cox T; Sainz B; Dusetti N; Greenhalf W; Rinaldi L; Costello E; Ghaneh P; Malats N; Büchler M; Pajic M; Biankin AV; Iovanna J; Neoptolemos J; Real FX
Gut; 2017 Sep; 66(9):1665-1676. PubMed ID: 27325420
[TBL] [Abstract][Full Text] [Related]
17. GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4α expression, and KRAS mutations.
Nakajima N; Yoshizawa A; Nakajima T; Hirata M; Furuhata A; Sumiyoshi S; Rokutan-Kurata M; Sonobe M; Menju T; Miyamoto E; Chen-Yoshikawa TF; Date H; Haga H
Histopathology; 2018 Jul; 73(1):38-48. PubMed ID: 29469192
[TBL] [Abstract][Full Text] [Related]
18. A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Zhu L; Wang X
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32024063
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes.
de Santiago I; Yau C; Heij L; Middleton MR; Markowetz F; Grabsch HI; Dustin ML; Sivakumar S
Int J Cancer; 2019 Aug; 145(4):1125-1137. PubMed ID: 30720864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
